# A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years

> **NCT06106581** · PHASE2 · COMPLETED · sponsor: **Valneva Austria GmbH** · enrollment: 304 (actual)

## Conditions studied

- Chikungunya Virus Infection

## Interventions

- **BIOLOGICAL:** VLA1553 full dose
- **BIOLOGICAL:** VLA1553 half dose
- **BIOLOGICAL:** Control

## Key facts

- **NCT ID:** NCT06106581
- **Lead sponsor:** Valneva Austria GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-12-18
- **Primary completion:** 2024-07-31
- **Final completion:** 2025-07-02
- **Target enrollment:** 304 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06106581

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06106581, "A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06106581. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*